Although preliminary and requiring validation in a larger cohort of mutation carriers, these findings suggest that circulating OPG levels may be predictive of subsequent breast cancer risk in women with a BRCA mutation, and that the integration of circulating OPG levels into existing risk prediction models will potentially enable us to more accurately identify women who are at the highest risk of developing disease. The gene discussed is TNFRSF11B; the disease is breast cancer.